<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02592798</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-566</org_study_id>
    <secondary_id>2015-005450-36</secondary_id>
    <nct_id>NCT02592798</nct_id>
  </id_info>
  <brief_title>Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)</brief_title>
  <official_title>A Phase II Randomized, Placebo-Controlled, Double-Blind, Parallel Arms With Switchover, Pilot Study to Evaluate the Efficacy and Safety of Intravenous Abatacept in Treatment Resistant Nephrotic Syndrome (Focal Segmental Glomerulosclerosis/ Minimal Change Disease)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is evaluate if abatacept is effective and safe in decreasing the
      level of protein loss in the urine in patients with excessive loss of protein in the urine
      (nephrotic syndrome) due to either focal segmental glomerulosclerosis (FSGS) or minimal
      change disease (MCD). Candidates must have a prior kidney biopsy with either diagnosis.
      Another kidney biopsy will not be required as part of the study. Candidates must have failed
      or be intolerant of prior therapy for their kidney disease. The failed or intolerant therapy
      must include corticosteroids and at least one other drug. Candidates can be adults and
      children over the age of 6. Abatacept will be administered by venous infusion every 4 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2016</start_date>
  <completion_date type="Anticipated">June 29, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 11, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects in Renal Response at Day 113</measure>
    <time_frame>Day 113</time_frame>
    <description>Proportion of subjects in Renal Response (reduction in baseline UPCR of ≥ 50% and to less than 3 with no worsening of baseline estimated glomerular filtration rate (eGFR: normal or ≥ 75% baseline if below normal at baseline)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in Urine Protein to Creatinine Ratio (UPCR) at Day 113</measure>
    <time_frame>Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in serum albumin at Day 113</measure>
    <time_frame>Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving complete remission</measure>
    <time_frame>Day 113</time_frame>
    <description>Proportion of subjects achieving complete remission (UPCR ≤ 0.3 with Estimated glomerular filtration rate (eGFR): normal or ≥ 75% baseline if below normal at baseline) at Day 113</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in PROMIS measures</measure>
    <time_frame>Approximately 113 days</time_frame>
    <description>Patient Reported Outcomes Measurement Information System (PROMIS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety measured by incidence, potential significance and clinical importance of AEs, SAEs, as determined by medical review of AE reports, vital sign measurements and results of physical examination and laboratory tests</measure>
    <time_frame>Approximately 113 days</time_frame>
    <description>Adverse Event (AE), Serious adverse event (SAE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with positive antibody response relative to baseline over time</measure>
    <time_frame>Approximately 113 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Nephrotic Syndrome</condition>
  <condition>Focal Segmental Glomerulosclerosis</condition>
  <condition>Minimal Change Disease</condition>
  <arm_group>
    <arm_group_label>Abatacept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abatacept intravenous injection every 28 days
Adults will use the weight-tiered dose: &lt; 60 kg: 500 mg, 60 to 100 kg: 750 mg, &gt; 100 kg: 1000 mg
Pediatric patients 6 to 17 years who weigh &lt; 75 kg will receive:10 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Normal saline or D5W (5% Dextrose in Water)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept</intervention_name>
    <arm_group_label>Abatacept</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>D5W</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>5% Dextrose in Water</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Male and female subjects ages ≥ 6 years

          -  Subjects resistant to corticosteroids, calcineurin inhibitors (cyclosporine and
             tacrolimus), sirolimus, mycophenolate mofetil (MMF), mycophenolic acid (MPA), or
             cyclophosphamide or intolerant to at least 2 of these

          -  UPCR ≥ 3 at screening

          -  FSGS or MCD confirmed by renal biopsy

          -  eGFR ≥ 45 for children and adults

          -  Concomitant use of angiotensin-converting-enzyme inhibitor (ACEi) or angiotensin
             receptor blocker (ARB) at stable doses for at least 2 weeks or have intolerance
             documented in the source documents maintained at the site

        Exclusion Criteria:

          -  Kidney diseases other than FSGS or MCD

          -  Collapsing FSGS

          -  Systemic lupus erythematosus

          -  Diabetes mellitus, both type 1 and type 2

          -  Clinically significant congestive heart failure

          -  Post renal transplantation, including relapsing post-transplant FSGS

          -  Body mass index (BMI): &gt; 40 in subjects ≥ 18 years of age and ≥ 99% percentile for
             subjects &lt; 18 years of age

        Other protocol defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University Of Alabama At Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Feig, Site 0001</last_name>
      <phone>205-638-9781</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Alabama-Birmingham-Parent Account</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmy Bell, Site 0028</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Institute</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Adler, Site 0009</last_name>
      <phone>310-991-6400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Thurman, Site 0016</last_name>
      <phone>303-724-0183</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's National Health System</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asha Moudgil, Site 0017</last_name>
      <phone>202-476-5370</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Miami Miller School Of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jayanthi Chandar, Site 0015</last_name>
      <phone>305-585-6726</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nemours Childrens Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Mathias, Site 0026</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322-1015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larry Greenbaum, Site 0004</last_name>
      <phone>404-712-9923</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rekha Agrawal, Site 0011</last_name>
      <phone>708-216-0291</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>NIH Clinical Center - NIDDK</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Kopp, Site 0005</last_name>
      <phone>301-594-3403</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boston Childrens Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Somers, Site 0007</last_name>
      <phone>617-355-6129</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brigham And Women'S Hosp Inc.</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Greka, Site 0002</last_name>
      <phone>617-525-5939</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Gipson, Site 0003</last_name>
      <phone>734-232-4852</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ladan Zand, Site 0010</last_name>
      <phone>507-266-1047</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Childrens Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tarak Srivastava, Site 0025</last_name>
      <phone>816-760-5594</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York University Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Trachtman, Site 0013</last_name>
      <phone>646-501-2663</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center (Cumc)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Appel, Site 0014</last_name>
      <phone>212-305-3273</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Levine Children'S Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Massengill, Site 0021</last_name>
      <phone>704-347-4052</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rasheed Gbadegesin, Site 0012</last_name>
      <phone>919-684-4246</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children'S Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stuart Goldstein, Site 0020</last_name>
      <phone>513-803-3295</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Metro Health System</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Schelling, Site 0006</last_name>
      <phone>216-778-7141</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Ayoub, Site 0029</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Hogan, Site 0008</last_name>
      <phone>215-615-4938</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital Of Pittsburgh Of Upmc</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnes Swiatecka-Urban, Site 0027</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renal Disease Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard Fischbach, Site 0022</last_name>
      <phone>214-358-2300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Brown, Site 0023</last_name>
      <phone>214-648-3438</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2015</study_first_submitted>
  <study_first_submitted_qc>October 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2015</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
    <mesh_term>Glomerulosclerosis, Focal Segmental</mesh_term>
    <mesh_term>Nephrosis, Lipoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

